Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Actiq Stories

2013-10-14 23:02:04

The law firm of Heygood, Orr & Pearson is announcing the launch of its new fentanyl pain patch website, Fentanyl Patch Lawsuits (http://fentanylpatchlawsuits.com/). The site will serve as a news and information resource for patients and their families whose lives have been affected by fentanyl prescriptions. Dallas, Texas (PRWEB) October 14, 2013 The law firm of Heygood, Orr & Pearson is announcing the launch of its new fentanyl pain patch website, Fentanyl Patch Lawsuits...

2013-02-04 16:25:36

TAMPA, Fla., Feb. 4, 2013 /PRNewswire/ -- myMatrixx, a pharmacy benefit management and ancillary medical services company serving workers' compensation announced today the release of a new case study resulting in savings of over $250,000 per year for one claimant. The study titled "Unmanageable or Simply Unmanaged? A Look Inside An Opioid Drug Treatment Case" reviews a clinical intervention with a catastrophic case including multiple opioids totaling over $27,000 a month. The case was brought...

2012-03-19 23:00:52

On March 12th 2012, BioDelivery Sciences International, Inc. announced that the U.S. re-launch of Onsolis (Fentanyl buccal soluble film) is being postponed until the product formulation can be modified to address two appearance issues raised by the U.S. Food and Drug Administration (FDA). Fentanyl (brand names Duragesic, Onsolis and others) is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an...

2011-08-02 15:10:00

FRAZER, Pa., Aug. 2, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2011 net sales of $730.1 million, a 2 percent increase compared to net sales of $712.4 million for the second quarter of 2010. Basic income per common share for the period was $1.54 compared to $1.18 for the second quarter of 2010. Excluding amortization expense and certain other items, adjusted net income for the second quarter of 2011 was $142.6 million, a 14 percent decrease versus...

2011-07-21 08:30:00

FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare...

2011-05-03 15:10:00

FRAZER, Pa., May 3, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported first quarter 2011 net sales of $736.0 million, a 28 percent increase compared to net sales of $576.7 million for the first quarter of 2010. Basic income per common share for the period was $2.79. Excluding amortization expense and certain other items, adjusted net income for the first quarter of 2011 was $158.4 million, a 10 percent increase over the same period in 2010. Basic adjusted income per...

2011-04-11 07:15:00

MISSISSAUGA, Ontario, April 11, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc. (NASDAQ: CEPH) for removal of Cephalon's current Board of Directors and election of its seven nominees in their place. Valeant compares its $73.00 per share all-cash offer, which would deliver immediate and certain...

2011-02-10 15:10:00

FRAZER, Pa., Feb. 10, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2010 net sales of $2.761 billion, a 28 percent increase compared to net sales of $2.152 billion for 2009. Basic income per common share for the year was $5.66. Excluding amortization expense and certain other items, adjusted net income for full year 2010 was $657 million, a 40 percent increase over the previous year. This exceeded the company's adjusted net income guidance range of $617 to $632...

2010-10-28 15:10:00

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2010 sales of $707.1 million, a 32 percent increase compared to sales of $535.2 million for the third quarter 2009. Basic income per common share for the quarter was $1.76. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $2.27, a 34 percent increase over the $1.70 for the third quarter of 2009. Adjusted net...

2010-07-27 15:10:00

FRAZER, Pa., July 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported second quarter 2010 sales of $712.4 million, a 32 percent increase compared to sales of $539.0 million for the second quarter 2009. Basic income per common share for the quarter was $1.18. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $2.20, an increase of 41 percent over the comparable figure of $1.56 for the same period in...